A Medical Student’s Call for Action Against Research Misconduct
By Eden Almasude,
The Hastings Center
| 06. 03. 2014
Untitled Document
According to the KMSP report for which I was interviewed, in 2007 a psychiatric research team led by Dr. Stephen Olson enrolled a mentally ill young man identified as Robert into a clinical trial for the experimental antipsychotic drug bifeprunox. Robert told KMSP that he was incompetent to consent, and that the psychiatric team used the threat of a significant medical bill to pressure him into the study. Despite Robert’s concerns about the safety of the drug, which was not FDA-approved, researchers minimized the study risks. Dr. Olson specifically noted in his clinical record that he told Robert that “enough patients have been treated to be more sure of its safety.”
Soon after Robert entered the study, the FDA rejected bifeprunox for marketing approval. Within months the sponsor of the trial, Solvay Pharmaceuticals, stopped all research after bifeprunox was linked to the death of a study subject in Europe due to liver failure. There is no record that Robert was ever informed of these developments.
Robert’s condition worsened and he began having abdominal pain so severe that he...
Related Articles
By Katherine Long, Ben Foldy, and Lingling Wei, The Wall Street Journal | 12.13.2025
Inside a closed Los Angeles courtroom, something wasn’t right.
Clerks working for family court Judge Amy Pellman were reviewing routine surrogacy petitions when they spotted an unusual pattern: the same name, again and again.
A Chinese billionaire was seeking parental...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Sarah Kliff, The New York Times | 12.10.2025
Micah Nerio had known since his early 30s that he wanted to be a father, even if he did not have a partner. He spent a decade saving up to pursue surrogacy, an expensive process where he would create embryos...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
